TG Therapeutics FY2025 EPS Forecast Boosted by HC Wainwright

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities research analysts at HC Wainwright raised their FY2025 earnings per share (EPS) estimates for TG Therapeutics in a research report issued to clients and investors on Wednesday, January 14th. HC Wainwright analyst E. Bodnar now forecasts that the biopharmaceutical company will earn $2.89 per share for the year, up from their prior estimate of $2.83. HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics’ Q4 2026 earnings at $0.47 EPS, FY2026 earnings at $1.28 EPS, FY2028 earnings at $2.38 EPS, FY2029 earnings at $3.02 EPS and FY2030 earnings at $3.96 EPS.

Other analysts have also recently issued reports about the company. Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a research note on Monday, December 29th. B. Riley upgraded TG Therapeutics to a “strong-buy” rating in a report on Tuesday, November 4th. JPMorgan Chase & Co. lifted their price objective on TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Wall Street Zen upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, December 14th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of TG Therapeutics in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, TG Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $50.75.

TG Therapeutics Price Performance

TGTX stock opened at $30.71 on Thursday. The stock has a market capitalization of $4.88 billion, a price-to-earnings ratio of 11.05 and a beta of 1.86. The firm’s 50-day moving average price is $30.80 and its two-hundred day moving average price is $32.56. The company has a current ratio of 3.82, a quick ratio of 2.89 and a debt-to-equity ratio of 0.40. TG Therapeutics has a 12-month low of $25.28 and a 12-month high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $2.19. The company had revenue of $161.71 million during the quarter, compared to analyst estimates of $152.12 million. TG Therapeutics had a net margin of 84.13% and a return on equity of 133.24%. The firm’s revenue was up 92.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.02 EPS.

Insiders Place Their Bets

In other TG Therapeutics news, Director Yann Echelard sold 5,000 shares of the stock in a transaction on Monday, November 24th. The stock was sold at an average price of $32.57, for a total value of $162,850.00. Following the completion of the transaction, the director owned 223,816 shares in the company, valued at approximately $7,289,687.12. This represents a 2.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.64% of the stock is currently owned by insiders.

Hedge Funds Weigh In On TG Therapeutics

Several large investors have recently made changes to their positions in TGTX. Congress Asset Management Co. purchased a new stake in shares of TG Therapeutics in the fourth quarter worth $57,307,000. Man Group plc grew its position in TG Therapeutics by 621.5% during the 3rd quarter. Man Group plc now owns 1,008,462 shares of the biopharmaceutical company’s stock valued at $36,431,000 after purchasing an additional 868,697 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in TG Therapeutics by 1,221.4% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 422,078 shares of the biopharmaceutical company’s stock valued at $15,191,000 after purchasing an additional 390,137 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in TG Therapeutics by 21.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock worth $75,683,000 after buying an additional 345,059 shares during the last quarter. Finally, Marex Group plc bought a new position in shares of TG Therapeutics in the second quarter worth approximately $10,017,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about TG Therapeutics

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Goldman Sachs note highlights a renewed bull case driven by accelerating Briumvi sales and sees ~32% upside to the stock, providing institutional validation for further gains. TG Therapeutics stock pops as Briumvi boom reignites bull case: Goldman Sachs sees room for 32% rally
• Positive Sentiment: Company preliminary Q4 and full-year 2025 results surprised to the upside (sales beat guidance) and management set a bullish 2026 revenue target while flagging multiple Briumvi pipeline milestones — fundamentals and forward guidance that support higher valuation. TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results
• Positive Sentiment: Retail trading interest surged, with coverage noting increased chatter and speculative buying — heightened retail demand can amplify intraday moves and volume. Retail traders are piling into TG Therapeutics – what’s driving the chatter?
• Positive Sentiment: Unusually large options activity — about 7,870 call contracts bought (roughly +119% vs. typical daily call volume) — signals speculative bullish positioning and likely contributes to upward pressure on the share price.
• Neutral Sentiment: HC Wainwright updated multiple EPS forecasts: they raised FY2025 estimates but trimmed FY2026–FY2030 estimates slightly in places while keeping a “Buy” rating and a $60 price target. The mix of upward and downward revisions makes the net near-term impact ambiguous but leaves a constructive medium-term target. (No direct article link provided.)
• Neutral Sentiment: Company entries indicate updated FY2025/FY2026 guidance entries (values not detailed in the data), which keeps attention on forthcoming formal guidance and quarterly filings for clarity.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.